Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NBI-1065845 by Neurocrine Biosciences for Treatment Resistant Depression: Likelihood of Approval
NBI-1065845 is under clinical development by Neurocrine Biosciences and currently in Phase II for Treatment Resistant Depression. According to GlobalData,...
NBI-1065845 by Neurocrine Biosciences for Major Depressive Disorder: Likelihood of Approval
NBI-1065845 is under clinical development by Neurocrine Biosciences and currently in Phase II for Major Depressive Disorder. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1065845?
NBI-1065845 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Treatment Resistant Depression. According...